HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of GR-89696 and the novel peripherally selective OP2 agonists, EMD-61569 and EMD-61747, against focal cerebral ischemia in the rat.

Abstract
We examined whether increases in blood-brain barrier (BBB) permeability occurring after stroke can be exploited to apply protective substances selectively to ischemic tissue. To do this, the actions of the peripherally selective OP2 agonists, EMD-61569 and EMD-61747, have been compared with those of the centrally acting OP2 agonist, GR-89696, in the rat permanent focal ischemia model. EMD-61569, EMD-61747 and GR-89696 all bound with high affinity to OP2 receptors and were potent agonists in the rabbit vas deferens functional assay. These substances also potently inhibited electrically-induced overflow of dopamine from slices of rat nucleus accumbens. EMD-61747 and EMD-61569 penetrate poorly into the CNS under normal conditions and reverse haloperidol-induced L-DOPA accumulation in the nucleus accumbens of the rat only at high doses, in contrast to GR-89696. Permanent unilateral occlusion of the middle cerebral artery (MCAO) was associated with a disruption of the BBB and an increase in the concentration of EMD-61747 in the area of the infarct. GR-89696 at a dose of 0.1 mg/kg s.c. produced a reduction in infarct volume by 38% after MCAO, EMD-61569 and EMD-61747 had no influence on swelling and ischemic damage. We conclude that EMD-61747 and EMD-61569 are potent OP2 agonists, which usually have a limited ability to penetrate the BBB. The change in the properties of the BBB in ischemic tissue was not sufficient to elicit neuroprotection, since both EMD-61747 and EMD-61569 were inactive in the focal ischemia model. Conversely, GR-89696 had a robust protective action, and probably powerful OP2-typical side effects as a consequence of its unrestricted central activity.
AuthorsA Barber, H M Bender, R Gottschlich, H E Greiner, J Harting, F Mauler, C A Seyfried
JournalMethods and findings in experimental and clinical pharmacology (Methods Find Exp Clin Pharmacol) Vol. 21 Issue 2 Pg. 105-13 (Mar 1999) ISSN: 0379-0355 [Print] Spain
PMID10327391 (Publication Type: Journal Article)
Chemical References
  • EMD 61569
  • EMD 61747
  • Neuroprotective Agents
  • Piperazines
  • Pyrroles
  • Pyrrolidines
  • Receptors, Opioid, kappa
  • GR 89696
  • Levodopa
Topics
  • Animals
  • Binding, Competitive (drug effects)
  • Brain Edema (drug therapy)
  • Brain Ischemia (drug therapy)
  • Cerebral Arteries (drug effects, physiology)
  • Levodopa (chemistry)
  • Ligation
  • Male
  • Neuroprotective Agents (therapeutic use)
  • Piperazines (therapeutic use)
  • Pyrroles (pharmacology)
  • Pyrrolidines (therapeutic use)
  • Rabbits
  • Rats
  • Rats, Inbred F344
  • Rats, Wistar
  • Receptors, Opioid, kappa (agonists)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: